During this clinical trial, treatment will be administered through intravenous infusion, which means the medication will be delivered directly into a vein.

The trial involves three medications: mirvetuximab soravtansine, carboplatin, and bevacizumab. All medications will be given as a concentrate for solution for infusion.

The specific combination of medications, dosage amounts, frequency of administration, and duration of treatment will be determined based on the substudy assigned. However, the exact dosing schedule and treatment duration are not specified in the available information.

Throughout the trial, regular monitoring will be conducted to assess how the treatment affects the body.

Specific attention will be given to monitoring for treatment-emergent adverse events, which are any unwanted medical occurrences that happen during or after treatment.

Eye-related side effects will be monitored, as the treatment may affect vision or eye health.

Monitoring will also include checking for peripheral neuropathy, which refers to nerve damage that can cause numbness, tingling, or pain, typically in the hands and feet.

Lung health will be assessed to detect any signs of pneumonitis or interstitial lung disease, which are conditions involving inflammation or scarring of lung tissue.

Regular assessments will be performed to measure how the cancer is responding to treatment.

These evaluations will follow standardized criteria called RECIST v1.1, which is a method used to measure changes in tumor size through imaging scans.

Blood tests will measure CA-125 levels, which is a protein that can indicate ovarian cancer activity. Changes in this marker will be assessed using specific criteria.

The duration of any positive response to treatment will be tracked to determine how long the cancer remains controlled.

Assessments will continue to monitor for progression-free survival, which measures the length of time during and after treatment that the cancer does not grow or spread.

The trial is expected to continue until approximately January 2029.

Regular visits will be required throughout the treatment period for medication administration, safety monitoring, and disease assessments.

The frequency and timing of these visits will be determined by the specific substudy protocol.

Participation will continue as long as the treatment is tolerated and the disease does not progress, or until other criteria for discontinuation are met.